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Abstract 
 
Objectives Cytokines have an important role in orchestrating the pathophysiology in 
autoimmune thyroid disease. The aim of the current study was to analyse the expression of 
interleukin (IL)-14 and IL-16 in the thyroid tissue of patients with Graves’ disease (GD), 
Hashimoto’s thyroiditis (HT) or multi-nodular goitre (MNG) and in that of normal individuals, 
in patients’ intra-thyroidal CD4
+
 and CD8
+
 T cells, and in patient and normal cultured thyroid 
follicular cells. 
Methods The expression of IL-14 and IL-16 mRNA and protein was investigated using 
reverse transcription-polymerase chain reaction (RT-PCR) amplification, and western 
blotting and ELISAs, respectively. 
Results IL-14 mRNA expression was detected in thyroid tissue from 8/9 GD, 3/4 HT and 3/13 
MNG patients and 1/6 normal individuals, and IL-16 mRNA expression in thyroid tissue from 
9/9 GD, 4/4 HT and 9/13 MNG patients and 4/6 normal individuals. IL-14 mRNA expression 
was detected in intra-thyroidal CD4
+
 and CD8
+
 T cells from 2/2 GD and 2/2 HT patients, 
while IL-16 mRNA was detected in samples from 1/2 HT but not in those from either GD 
patients. IL-14 and IL-16 mRNA expression was found in thyroid follicular cells derived from 
2/2 patients with GD and 1/1 normal individual. 
 IL-14 protein was detected in thyroid tissue from 6/6 GD, 1/1 HT and 0/6 MNG 
patients and 0/6 normal individuals, and IL-16 protein in thyroid tissue from 6/6 GD, 1/1 HT 
and 1/6 MNG patients and 0/6 normal individuals. Expression of IL-14 protein was 
stimulated in thyroid follicular cells derived from two GD patients and one normal individual 
by peripheral blood mononuclear cell (PBMC)-conditioned medium. Treatment of 
thyrocytes from two GD patients and one normal individual with PBMC-conditioned 
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medium and tumour necrosis factor (TNF)-α stimulated IL-16 protein expression. In normal 
thyrocytes, IL-16 protein synthesis was induced also by IL-1β, IL-17A, IL-4 and transforming 
growth factor (TGF)-β.  
Conclusions The data provide evidence that the intra-thyroidal production of IL-14 and IL-16 
is associated with the pathogenesis of autoimmune thyroid disease. Thyroid follicular cells 
display the ability to express IL-14 and IL-16 mRNA and can be stimulated to express IL-16 
protein, by a panel of cytokines, and IL-14 protein, by as yet unidentified factors.  
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Introduction 
 
Graves’ disease (GD) and Hashimoto’s thyroiditis (HT) are the two most common clinical 
expressions of thyroid dysfunction due to autoimmunity.
1
 HT is characterised by infiltration 
of thyroid-specific T lymphocytes and other immune cells, thyroid enlargement and fibrosis, 
and progressive destruction of thyrocytes, eventually resulting in hypothyroidism.
2
 Patients 
with GD may show lymphocytic infiltration and some damage to the thyroid, but the disease 
is characterized by hyperthyroidism due to excessive production of thyroid hormone 
induced by specific autoantibodies against the thyrotropin receptor.
3
 Although several 
factors, including genetic, hormonal, and environmental, have been implicated in the 
initiation and/or development of thyroid autoimmunity,
4
 the changes associated with the 
pathophysiology of autoimmune thyroid disease are orchestrated by an array of cytokines.
5
 
Particularly, pro-inflammatory Th1- and Th17-specific cytokines, which can be produced by 
thyroid follicular cells as well as thyroid-infiltrating T lymphocytes, have a role in promoting 
thyroid autoimmunity.
6-9
  
 Interleukin (IL)-14 is produced mainly by T lymphocytes and acts to stimulate B cell 
proliferation, expand selected B cell subgroups, and inhibit antibody secretion.
10
 It has been 
implicated in the pathogenesis of autoimmune diseases, systemic lupus erythematosus and 
Sjögren's syndrome.
11,12
 Given the importance of the humoral immune response in 
autoimmune thyroid disease, particularly GD, IL-14 may be directly involved in initiation 
and/or progression of the autoimmune process. In contrast, IL-16 is involved in cellular 
immune responses
13,14
 and is produced by several cell types including epithelial cells, 
fibroblasts, monocytes, lymphocytes and eosinophils.
15-18
 This cytokine plays a role in a 
number of auto-inflammatory conditions, including rheumatoid arthritis, Crohn’s disease 
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and systemic lupus erythematosus.
19-21 
Moreover, previous evidence suggests a role for IL-
16 in thyroid autoimmunity.
22,23
 
Given the potential for involvement of IL-14 and IL-16 in autoimmune thyroid disease 
pathogenesis, the aim of the current study was to analyse the expression of IL-14 and IL-16 
in the thyroid tissue of patients with either GD, HT or multi-nodular goitre (MNG) and in that 
of normal individuals, in intra-thyroidal CD4
+
 and CD8
+
 T cells derived from GD and HT 
patients, and in primary thyrocytes taken from diseased and normal thyroids, as well as in 
the human thyroid cell line HT-ori3. Overall, this study will aim to establish the role of IL-14 
and IL-16 in autoimmune thyroid disease which is an important step to fully understand 
disease pathogenesis and uncover potential future therapeutic targets. 
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Materials and methods 
 
Patients and thyroid tissue samples 
Local ethical committee approval was obtained for the study and informed written consent 
was obtained from all participants prior to inclusion in the study. Disease diagnosis was 
confirmed in all GD (n = 9), HT (n = 4) and non-toxic, non-autoimmune MNG (n = 13) patients 
by biochemical testing and histological examination. All HT patients had high antibody titres 
against thyroid peroxidase, whereas seven out of nine GD patients had raised anti-thyroid 
peroxidase antibody titres, with data unavailable for the remaining two. All patients with HT 
and GD had been treated with thyroxine and carbimazole, respectively, prior to surgery. 
Surgery in the HT patients was performed either for diagnostic purposes, because 
lymphoma was suspected (but not subsequently confirmed) or to remove a painful or a 
cosmetically disfiguring goitre. Patient thyroidectomy specimens were either snap-frozen in 
liquid nitrogen or processed to obtain either thyroid-infiltrating immune cells or thyroid 
follicular cells. Snap-frozen thyroid tissue samples were also obtained from six normal 
individuals (ProteoGenex, Culver City, CA, USA). 
 
Isolation of intra-thyroidal CD4
+
 and CD
+
 T cells 
Intra-thyroidal lymphocytes were prepared from GD and HT patient thyroidectomy 
specimens by collagenase/Dispase digestion as described previously.
24
 CD4
+
 and CD8
+
 T cells 
were isolated using magnetic Dynabeads
®
 M-450 beads (Dynal Biotech, Oslo, Norway), 
according to the manufacturer’s protocol. 
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Thyroid follicular cells  
The human thyroid cell line HT-ori3 was established by transfection of normal human 
thyrocytes with a plasmid-borne origin-defective SV40 genome, as previously described.
25
 
Thyroid follicular cells were prepared from GD patient thyroidectomy specimens using 
methods described elsewhere.
26
 Normal primary thyrocytes were obtained from Applied 
Biological Materials Inc. (Richmond, BC, Canada). Thyrocytes were cultured as detailed 
before.
27
 
 
Reverse transcription-polymerase chain reaction (RT-PCR) amplification  
RNA was extracted from thyroid tissue, intra-thyroidal lymphocytes and cultured thyrocytes 
using TRIZOL® LS reagent (Life Technologies Ltd., Paisley, UK) according to the 
manufacturer's protocol. Moloney murine leukaemia virus reverse transcriptase (MMLV-RT; 
Promega, Southampton, UK) was used to synthesise cDNA, as previously described.
27 
Oligonucleotide primers (Life Technologies Ltd.) for PCR amplification of cDNA samples were 
designed according to previously published DNA sequences of IL-14
10
 and IL-16.
13
  The 
primer sequences were  5’-CAGCTCATACTGCTCATTCA-3’ (forward) and 5’-
TCCTACAGAAAAAGCAGAGC-3’ (reverse) for IL-14, and 5’-ATTCACTCATACATCTGGCC-3’ 
(forward) and 5’-TGCTTCACCTGTACTCCTCT-3’ (reverse) for IL-16. The primer sequences for 
β−actin have been described previously.
27
 PCR amplification reactions were performed as 
detailed earlier,
6
 with 27-29, 30-32 and 22-24 cycles used for IL-14, IL-16 and β-actin 
amplification, respectively. Control PCR amplifications without cDNA were carried out in 
parallel and were consistently negative. PCR amplification products were separated in 1% 
(w/v) agarose gels and their identification confirmed by Southern blotting and hybridisation 
using internal oligonucleotide probes (Life Technologies Ltd.), as previously described.
27
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Probes used were 5’-TCAGCCAGCTCCATGTTC-3’ for IL-14,
10
 and 5’-TGAATGCTTATAGGTGGC-
3’ for IL-16.
13
  The probe for β-actin has been detailed elsewhere.
24
 
 
Preparation of protein extracts from thyroid tissue and cultured thyrocytes 
Proteins were extracted from thyroid tissue and cultured thyroid follicular cells using 
TRIZOL® LS reagent (Life Technologies Ltd.) according to the manufacturer's protocol. 
Protein concentrations were determined using a Bio-Rad Protein Assay Kit (Bio-Rad 
Laboratories Ltd., Hemel Hempstead, UK).  
 
Western blotting 
Equivalent amounts of total protein in thyroid tissue or thyrocyte extracts were separated in 
SDS-polyacrylamide gels and transferred to Whatman™ Westran® Clear Signal 
polyvinylidene difluoride membrane (GE Healthcare Life Sciences, Little Chalfont, UK) using 
standard techniques. After treating membranes with Blocking Reagent (Roche Diagnostics, 
Mannheim, Germany), primary anti-IL-14 (Santa Cruz Biotechnology, Inc., Dallas, TX, USA) or 
anti-IL-16 (Santa Cruz Biotechnology, Inc.) antibody was applied to them at the required 
dilution in PBS/0.5 % (v/v) Blocking Reagent (Roche Diagnostics) before incubation with 
shaking at room temperature for 1.5 h. Secondary antibody conjugated to horseradish 
peroxidase (Santa Cruz Biotechnology, Inc.) at the required dilution in PBS/0.5 % (v/v) 
Blocking Reagent was applied to washed membranes prior to incubating them for 1 h at 
room temperature with shaking. Following washing, binding of the secondary antibody to 
the membranes was detected using a BM Chemiluminescence Blotting Substrate (POD) Kit 
(Roche Diagnostics) and exposure to X-ray film, as explained in the manufacturer’s manual.  
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Cytokine treatment of cultured thyroid follicular cells 
For analysing the effects of cytokines and TSH on IL-14 and IL-16 protein expression, thyroid 
follicular cell cultures were grown to confluence in 25-cm
2
 flasks and were then left 
untreated or treated for 6, 12 and 24 h with either IL-1α (100 U/ml; Hoffman-La Roche Inc., 
Nutley, NJ, USA), bovine TSH (100 µU/ml; National Institute for Biological Standards and 
Control, Potters Bar, UK), interferon (IFN)-γ (100 U/µl; Roche Diagnostics GmbH, Mannheim, 
Germany), tumour necrosis factor (TNF)-α (100 U/ml; CN Biosciences Ltd., Nottingham, UK), 
IL-1β (10 ng/ml), IL-17A (20 ng/ml), IL-4 (10 ng/ml) or transforming growth factor (TGF)-β 
(10 ng/ml)  (all from R&D Systems, Inc., Minneapolis, MN, USA), as detailed previously.
27
 To 
provide a positive control for the induction of IL-14 and IL-16 protein expression, peripheral 
blood mononuclear cells (PBMC) from a healthy individual were treated with 1 µg/ml of 
phytohaemagglutinin M (Life Technologies Ltd.) for 24 h and the conditioned culture 
medium centrifuged at 500 g for 10 min, sterilised by filtration, and then used to treat 
cultured thyrocytes for 6, 12 and 24 h. Samples of thyroid follicular cell culture supernatants 
were collected prior to treatment at 0 h and at the stated time points, centrifuged at 500 g 
for 10 min, and then analysed for IL-14 and IL-16 protein levels in IL-14- or IL-16-specific 
ELISAs, respectively. After 24 h, untreated and treated thyrocytes were collected for the 
preparation of protein extracts, as detailed above. 
 
Cytokine ELISAs 
IL-14- and IL-16-specific ELISAs were used according to the manufacturers’ protocols. The IL-
14 ELISA (Cloud-Clone Corp, Houston, TX, USA) had an assay range of 15.6-1000 pg/ml, a 
sensitivity of < 5.6 pg/ml, and intra- and inter-assay coefficients of variation of < 10%. The IL-
16 ELISA (Thermo Scientific, Inc., Rockford, IL, USA) had an assay range of 0-2000 pg/ml, a 
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sensitivity of < 8.0 pg/ml, and intra- and inter-assay coefficients of variation of < 10%. In the 
ELISAs, mean OD450 values from duplicate samples of thyrocyte culture supernatants were 
corrected for background using the appropriate 0 h mean OD450 value. IL-14 and IL-16 
protein levels were then calculated as pg/ml from the appropriate standard curve.  
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Results 
 
IL-14 and IL-16 mRNA and protein expression in thyroid tissue samples 
The expression of IL-14 and IL-16 mRNA was analysed in thyroid tissue using RT-PCR 
amplification. IL-14 mRNA expression was detected in thyroid tissue from 8/9 GD, 3/4 HT 
and 3/13 MNG patients, as well as 1/6 normal individuals (Fig. 1a). IL-16 mRNA was found in 
thyroid tissue from 9/9 GD, 4/4 HT and 9/13 MNG patients, in addition to 4/6 normal 
individuals (Fig. 1a). 
The expression of IL-14 and IL-16 protein was analysed in thyroid tissue extracts using 
western blotting. IL-14 protein was detected as a 70-kD band in thyroid tissue extracts 
derived from 6/6 GD and 1/1 HT patients, but not in any samples taken from six MNG 
patients or six normal individuals (Fig. 2a). This was greater than the expected molecular 
weight of 60-62 kD.
28
 IL-16 protein was identified at 68 kD in thyroid tissue extracts from 6/6 
GD, 1/1 HT and 1/6 MNG patients, but was not found in any of six normal individuals (Fig. 
2a). The protein detected by western blotting was assumed to represent the precursor form 
of IL-16, pro-IL-16, which has a molecular weight estimated from its cDNA sequence of 69 
kD, in comparison to the secreted 14-kDa active C-terminal part of the cytokine.
29
 
 
IL-14 and IL-16 mRNA expression in intra-thyroidal CD4
+
 and CD8
+ 
T cells 
As the thyroids of patients with autoimmune thyroid disease are infiltrated with T 
lymphocytes which could be a source of IL-14 and IL-16 in the tissue, the expression of 
mRNA for both cytokines was analysed by RT-PCR amplification in intra-thyroidal CD4
+
 and 
CD8
+ 
T cells derived from two GD and two HT patients. IL-14 mRNA was detected in both 
intra-thyroidal CD4
+
 and CD8
+
 T cells from all four patients (Fig. 1b). In contrast, IL-16 mRNA 
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was detected in intra-thyroidal CD4
+
 and CD8
+
 T cells derived from only one of the two HT 
patients (Fig. 1b) and in none of the samples taken from the two GD patients.  
 
IL-14 and IL-16 mRNA and protein expression in thyroid follicular cells  
To investigate whether thyroid follicular cells could be a source of IL-14 and IL-16 in the 
thyroids of autoimmune disease patients, the expression of both cytokines in terms of 
mRNA and protein was analysed. IL-14 and IL-16 mRNA expression was detected by RT-PCR 
amplification in cultured HT-ori3 cells and in thyroid follicular cells derived from two 
patients with GD and one normal individual (Fig. 1c). 
By western blotting, IL-14 and IL-16 proteins were not detectable in extracts of 
cultured HT-ori3 cells or cultured thyroid follicular cells derived from two patients with GD 
and from one normal individual (Fig. 2b). In contrast, both IL-14 and IL-16 proteins were 
evident in extracts of all thyrocyte cultures following treatment with PBMC-conditioned 
medium (Fig. 2b).  
 
Effect of cytokine and TSH treatment on IL-14 and IL-16 protein expression by cultured 
thyrocytes 
To analyse the potential for cytokines and TSH to affect the expression of IL-14 and IL-16 
protein by thyrocytes, cultured HT-ori3 cells and thyroid follicular cells derived from two 
patients with GD and from one normal individual, were treated with IL-1β, IL-1α, IL-17A, IL-
4, TGF-β, TNF-α, IFN-γ, PBMC-conditioned medium and TSH. IL-14- and IL-16-specific ELISAs 
were used subsequently to detect the levels of IL-14 and IL-16 protein expressed and 
secreted into the culture medium by untreated and treated cultured thyrocytes.  
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The results showed that PMBC-conditioned medium induced IL-14 protein expression, 
which was detected after 6 h of stimulation, by HT-ori3 cells, thyrocytes from GD patients, 
and thyroid follicular cells from a normal individual (Fig. 3a-c). IL-14 protein expression was 
not detectable by HT-ori3 cells, thyroid follicular cells from GD patients or thyrocytes from a 
normal individual (Fig. 3a-c) even after treatment for 24 h with IL-1α, IFN-γ, TSH or TNF-α. 
Likewise, TGF-β, IL-1β, IL-4 and IL-17A were not stimulatory factors for IL-14 protein 
expression by HT-ori3 cells (Fig. 3a) or by thyrocytes from a normal individual (Fig. 3c).  
IL-16 protein expression by all thyrocyte cultures was increased following stimulation 
with either TNF-α for 24 h or PBMC-conditioned medium for 6 h, when compared with 
untreated thyroid follicular cells (Fig. 3d-f). In addition, 6-h stimulation of HT-ori3 cells and 
thyrocytes from a normal individual with IL-1β, IL-17A, IL-4 or TGF-β resulted in increases in 
IL-16 protein expression when compared with untreated cultures at the same time point 
(Fig. 3e and f). IL-16 protein expression by all thyrocyte cultures remained undetectable at 
24 h without treatment and following stimulation with either IL-1α, IFN-γ or TSH (Fig. 3d-f). 
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Discussion 
 
IL-14 is produced by B cells, T cells and dendritic cells, and enhances B cell proliferation, 
increases the sub-population of memory B cells and prevents the secretion of 
immunoglobulins.
10
 In the present study, novel findings in relation to IL-14 expression in 
autoimmune thyroid disease patients are reported. IL-14 mRNA expression was detected in 
the majority of GD and HT patient thyroid tissue samples, but was only evident in a minority 
of MNG patients and normal individuals. IL-14 protein was found in GD and HT patient 
thyroid tissue, but not in MNG patients or normal individuals. 
Next, the cellular source of IL-14 mRNA and protein in thyroid tissue affected by 
autoimmune disease was investigated. Thyroid-infiltrating lymphocytes isolated from HT 
and GD patients expressed IL-14 mRNA, as did cultured thyroid follicular cells derived from 
patients with GD and normal individuals. However, despite clear expression of IL-14 mRNA 
in thyroid follicular cells in vitro, IL-14 mRNA was detected in thyroid tissue samples from 
only three of 13 MNG patients and one of six normal individuals even after PCR 
amplification using a high cycle number. It could be that unknown inhibitory factors operate 
to suppress in vivo IL-14 mRNA expression by thyrocytes in MNG and normal thyroid tissue. 
Concerning IL-14 protein expression by thyrocytes, this was apparent only after 
stimulation with PBMC-conditioned medium. None of the cytokines tested nor TSH induced 
production of IL-14 protein by cultured thyroid follicular cells, indicating that some novel 
combination of factors in the conditioned medium is most likely to be responsible. Overall, 
the data suggest that both suitably stimulated thyroid follicular cells and infiltrating T cells 
are potential sources of the IL-14 protein that is found in the thyroid tissue of patients with 
autoimmune thyroid disease. By producing IL-14, both cell types may play a part in driving 
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the intra-thyroidal production of thyroid autoantibodies,
30
 given the importance of the 
cytokine in B cell proliferation, memory B cell production and immunoglobulin synthesis.  
IL-16 has a key role in inflammatory and autoimmune processes. It attracts CD4
+
 T 
cells, stimulates resting T cells,
 
and enhances the production of pro-inflammatory cytokines 
by immune-response cells.
13
 In this study, IL-16 mRNA expression was found in all GD and 
HT thyroids and in the thyroid tissue of the majority of MNG patients and normal 
individuals. IL-16 protein was detected in thyroid tissue extracts from all of the GD and HT 
patients analysed, but was not evident in most MNG patient thyroids and not at all in 
normal individuals. These results are consistent with a previous report concerning IL-16 
expression in thyroids affected by autoimmunity.
22
 
Having detected IL-16 mRNA in the majority of thyroid tissue and protein expression in 
diseased thyroids, it was necessary to determine which cells in the thyroid were able to 
express this cytokine. IL-16 mRNA expression was not evident in intra-thyroidal CD4
+
 and 
CD8
+
 T cells derived from the majority of patients with GD or HT, although IL-16 mRNA and 
IL-16 protein are constitutively expressed in T lymphocytes from normal individuals.
31
 
Expression of IL-16 mRNA was, however, detected in thyroid follicular cells whether derived 
from patients with autoimmune or non-autoimmune thyroid conditions or from normal 
individuals. This result is analogous to earlier reports in which constitutive IL-16 mRNA 
expression by thyrocytes in vitro has been shown.
22
 Similarly, fibroblasts from normal and 
GD thyroids constitutively express IL-16 mRNA.
32
  
With regard to IL-16 protein expression in thyrocytes, earlier studies reported that this 
did not occur in unstimulated cultured thyroid follicular cells and could only be detected 
following treatment of cultures with either IL-1β, TNF-α, IL-4 or TGF-β, although not by IFN-γ 
nor TSH.
22
 These observations were confirmed in the present study. There have also been 
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similar discoveries with respect to thyroid-derived fibroblasts from patients with GD: 
expression of IL-16 protein is stimulated by IL-1β and TNF-α.
32
 The finding that IL-16 protein 
expression in cultured thyrocytes can be induced by IL-17A is novel, although this pro-
inflammatory cytokine does increase markedly the production of IL-16 in synovial fibroblasts 
from patients with rheumatoid arthritis.
33
 Interestingly, IL-16 synthesis can be induced in 
cultured thyroid follicular cells by GD patient IgG and this is suggested to signal via the 
insulin-like growth factor-1 receptor, not the thyrotropin receptor, autoimmunity against 
which is the basis for the development of GD.
23
 Indeed, we found no evidence that TSH-
stimulation of the thyrotropin receptor caused the production of IL-16 in cultured 
thyrocytes. 
Notably, the expression of IL-16 protein by thyrocyte cultures following cytokine-
stimulation showed the same pattern whether from the thyroid of patients with GD or 
normal individuals. However, the detection of IL-16 protein in the thyroid tissue of GD and 
HT patients, but not in normal individuals, would suggest there is increased expression of 
this cytokine by thyrocytes in diseased versus normal thyroid glands. This may result from 
inflammatory factors present in HT and GD thyroids which drive the expression of IL-16 
protein by thyroid follicular cells. As a source of IL-16, thyrocytes may play a role, along with 
thyroidal fibroblasts,
32
 in CD4
+
 cell recruitment to and activation within the thyroid gland.  
In summary, the current study demonstrates that IL-14 and IL-16 are expressed in GD 
and HT thyroid tissue, suggesting an involvement of these cytokines in disease 
pathogenesis. Furthermore, thyroid follicular cells are able to produce IL-14 and IL-16, 
emphasising a potential role for these cells in promoting thyroid autoimmunity.  
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Figure Legends 
 
Fig. 1. IL-14 and IL-16 mRNA expression in thyroid tissue, intra-thyroidal lymphocytes and 
cultured thyrocytes. The results of RT-PCR amplification are shown for: (a) thyroid tissue 
samples from each of four patients with GD, HT or MNG and from four normal individuals; 
(b) intra-thyroidal CD4
+
 and CD8
+
 T cells derived from a patient with GD and a patient with 
HT; and (c) cultured HT-ori3 cells and cultured thyroid follicular cells derived from a patient 
with GD and a normal individual. PCR amplification products were identified at 319, 399 and 
560 base-pairs for IL-14, IL-16, and β-actin, respectively.  
 
Fig. 2. IL-14 and IL-16 protein expression in thyroid tissue and cultured thyrocytes. The 
results of western blotting are shown for: (a) thyroid tissue samples from a patient with 
either GD, HT or MNG and from a normal individual; and (b) cultured HT-ori3 (O) cells, and 
cultured thyroid follicular cells derived from a patient with GD and a normal (N) individual 
both untreated and treated with PBMC-conditioned medium for 24 h. IL-14 and IL-16 
proteins were identified at 70 kD and 68 kD, respectively. 
 
Fig. 3. Effect of treatment with cytokines, PMBC-conditioned medium and TSH on the 
expression of IL-14 and IL-16 protein by cultured thyrocytes. The results of IL-14- and IL-16-
specific ELISAs with IL-14 and IL-16 levels expressed as pg/ml (mean ± SD of two 
experiments) are shown, respectively, for: (a and d) HT-ori3 cells; (b and e) thyroid follicular 
cells from a GD patient; and (c and f) thyroid follicular cells from a normal individual.  
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Fig. 1. IL-14 and IL-16 mRNA expression in thyroid tissue, intra-thyroidal lymphocytes and cultured 
thyrocytes. The results of RT-PCR amplification are shown for: (a) thyroid tissue samples from each of four 
patients with GD, HT or MNG and from four normal individuals; (b) intra-thyroidal CD4+ and CD8+ T cells 
derived from a patient with GD and a patient with HT; and (c) cultured HT-ori3 cells and cultured thyroid 
follicular cells derived from a patient with GD and a normal individual. PCR amplification products were 
identified at 319, 399 and 560 base-pairs for IL-14, IL-16, and ββ-actin, respectively.  
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Fig. 1. IL-14 and IL-16 mRNA expression in thyroid tissue, intra-thyroidal lymphocytes and cultured 
thyrocytes. The results of RT-PCR amplification are shown for: (a) thyroid tissue samples from each of four 
patients with GD, HT or MNG and from four normal individuals; (b) intra-thyroidal CD4+ and CD8+ T cells 
derived from a patient with GD and a patient with HT; and (c) cultured HT-ori3 cells and cultured thyroid 
follicular cells derived from a patient with GD and a normal individual. PCR amplification products were 
identified at 319, 399 and 560 base-pairs for IL-14, IL-16, and ββ-actin, respectively.  
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Fig. 1. IL-14 and IL-16 mRNA expression in thyroid tissue, intra-thyroidal lymphocytes and cultured 
thyrocytes. The results of RT-PCR amplification are shown for: (a) thyroid tissue samples from each of four 
patients with GD, HT or MNG and from four normal individuals; (b) intra-thyroidal CD4+ and CD8+ T cells 
derived from a patient with GD and a patient with HT; and (c) cultured HT-ori3 cells and cultured thyroid 
follicular cells derived from a patient with GD and a normal individual. PCR amplification products were 
identified at 319, 399 and 560 base-pairs for IL-14, IL-16, and ββ-actin, respectively.  
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Fig. 2. IL-14 and IL-16 protein expression in thyroid tissue and cultured thyrocytes. The results of western 
blotting are shown for: (a) thyroid tissue samples from a patient with either GD, HT or MNG and from a 
normal individual; and (b) cultured HT-ori3 (O) cells, and cultured thyroid follicular cells derived from a 
patient with GD and a normal (N) individual both untreated and treated with PBMC-conditioned medium for 
24 h. IL-14 and IL-16 proteins were identified at 70 kD and 68 kD, respectively.  
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Fig. 2. IL-14 and IL-16 protein expression in thyroid tissue and cultured thyrocytes. The results of western 
blotting are shown for: (a) thyroid tissue samples from a patient with either GD, HT or MNG and from a 
normal individual; and (b) cultured HT-ori3 (O) cells, and cultured thyroid follicular cells derived from a 
patient with GD and a normal (N) individual both untreated and treated with PBMC-conditioned medium for 
24 h. IL-14 and IL-16 proteins were identified at 70 kD and 68 kD, respectively.  
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Fig. 3. Effect of treatment with cytokines, PMBC-conditioned medium and TSH on the expression of IL-14 
and IL-16 protein by cultured thyrocytes. The results of IL-14- and IL-16-specific ELISAs with IL-14 and IL-
16 levels expressed as pg/ml (mean ± SD of two experiments) are shown, respectively, for: (a and d) HT-
ori3 cells; (b and e) thyroid follicular cells from a GD patient; and (c and f) thyroid follicular cells from a 
normal individual.  
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Fig. 3. Effect of treatment with cytokines, PMBC-conditioned medium and TSH on the expression of IL-14 
and IL-16 protein by cultured thyrocytes. The results of IL-14- and IL-16-specific ELISAs with IL-14 and IL-
16 levels expressed as pg/ml (mean ± SD of two experiments) are shown, respectively, for: (a and d) HT-
ori3 cells; (b and e) thyroid follicular cells from a GD patient; and (c and f) thyroid follicular cells from a 
normal individual.  
91x66mm (300 x 300 DPI)  
 
 
Page 30 of 34Clinical Endocrinology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
  
 
 
Fig. 3. Effect of treatment with cytokines, PMBC-conditioned medium and TSH on the expression of IL-14 
and IL-16 protein by cultured thyrocytes. The results of IL-14- and IL-16-specific ELISAs with IL-14 and IL-
16 levels expressed as pg/ml (mean ± SD of two experiments) are shown, respectively, for: (a and d) HT-
ori3 cells; (b and e) thyroid follicular cells from a GD patient; and (c and f) thyroid follicular cells from a 
normal individual.  
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Fig. 3. Effect of treatment with cytokines, PMBC-conditioned medium and TSH on the expression of IL-14 
and IL-16 protein by cultured thyrocytes. The results of IL-14- and IL-16-specific ELISAs with IL-14 and IL-
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Fig. 3. Effect of treatment with cytokines, PMBC-conditioned medium and TSH on the expression of IL-14 
and IL-16 protein by cultured thyrocytes. The results of IL-14- and IL-16-specific ELISAs with IL-14 and IL-
16 levels expressed as pg/ml (mean ± SD of two experiments) are shown, respectively, for: (a and d) HT-
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